BioMarin betting big on smaller patient groups - San Francisco Business Times
BioMarin Pharmaceutical shares rise after possible takeover from Roche
BioMarin was ranked fourth on the 2019 list of "America's Best Midsize Employers" by Forbe's magazine
15. Jean-Jacques Bienaimé | FiercePharma
Jean-Jacques Bienaime
On the Line: BioMarin Pharma's CEO Jean Jacques Bienaime
Jean Jacques Bienaime Sells 1,500 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Stock - Opera News
J.P. Morgan Healthcare Conference is under way: early themes and a podcast - San Francisco Business Times
Michel Vounatsos vs Jean Jacques Bienaime | Comparably
BioMarin (NASDAQ: BMRN) sues to stop Dr. Reddy's (NYSE: RDY) from selling generic version of PKU drug Kuvan - San Francisco Business Times
Jean-Jacques Bienaime Archives - Business & Finance | Business & Finance
jean-jacques-bienaime-biomarin-ceo | North Bay Life Science Alliance
Jean-Jacques Bienaimé (76) – 1st Alumnus with the title of ESCP Doctor Honoris Causa – ESCP
Jean Reno - Wikipedia
Biotech SF: BioMarin shares rise on data from late-stage rare disease trial
Jan-Jacques Bienaime with Lana Bondar
Jennifer Beinaime with Jean-Jacques Bienaime
People | Nature Biotechnology
Jean-Jacques Bienaime with Jennifer Kano
BioMarin Pharmaceutical (NASDAQ: BMRN) wins FDA approval for $700,000 Batten disease drug Brineura - San Francisco Business Times
Jennifer Bienaime with Jean-Jacques Bienaime
Emma Pey - Quality Business Operations Technical Manager - BioMarin Pharmaceutical Inc. | LinkedIn
Kim Dolan - Brand Manager, North America PKU - BioMarin Pharmaceutical Inc. | LinkedIn
